Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Maciej Jaromin,Tomasz Konecki,Piotr Kutwin

DOI: https://doi.org/10.3390/cancers16071366

2024-03-31

Cancers

Abstract:Bladder cancer is the 10th most popular cancer in the world, and non-muscle-invasive bladder cancer (NMIBC) is diagnosed in ~80% of all cases. Treatments for NMIBC include transurethral resection of the bladder tumor (TURBT) and intravesical instillations of Bacillus Calmette-Guérin (BCG). Treatment of BCG-unresponsive tumors is scarce and usually leads to Radical Cystectomy. In this paper, we review recent advancements in conservative treatment of BCG-unresponsive tumors. The main focus of the paper is FDA-approved medications: Pembrolizumab and Nadofaragene Firadenovec (Adstiladrin). Other, less researched therapeutic possibilities are also included, namely: N-803 immunotherapy, TAR-200 and TAR-210 intravesical delivery systems and combined Cabazitaxel, Gemcitabine and Cisplatin chemotherapy. Conservative treatment and delaying radical cystectomy would greatly benefit patients' quality of life; it is undoubtedly the future of BCG-unresponsive NMIBC.

oncology

What problem does this paper attempt to address?

The paper primarily explores new treatment methods for patients with non-muscle invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) therapy. The paper first introduces the basic situation of bladder cancer and its status in urological cancers, emphasizing that non-muscle invasive bladder cancer is one of the most common types.

For cases of BCG treatment failure or non-response, the traditional approach is usually radical cystectomy, but this surgery significantly impacts the patient's quality of life. Therefore, researchers are exploring new conservative treatment methods to avoid or delay this surgery.

The paper focuses on several new treatment methods:

1. **FDA Approved Drugs**: Including Pembrolizumab and Nadofaragene Firadenovec (Adstiladrin). Both drugs have been proven effective in treating non-muscle invasive bladder cancer patients who do not respond to BCG.

2. **Immunotherapy**: For example, N-803 immunotherapy, which can promote the proliferation and activation of CD8+ T cells and NK cells, thereby enhancing the immune response to tumors.

3. **Other Treatment Options**: Such as the local delivery systems of TAR-200 and TAR-210, as well as combination chemotherapy with Cabazitaxel, Gemcitabine, and Cisplatin.

The research and development of these new methods aim to provide more effective treatment options for non-muscle invasive bladder cancer patients who are unresponsive to BCG therapy, thereby improving their quality of life and reducing the need for radical cystectomy. These research findings are of great significance for improving the prognosis of such patients.